Lantern Pharma (LTRN) Tops Q2 EPS by 13c
Tweet
Share
E-mailGet Alerts LTRN Hot Sheet
Join SI Premium – FREE
Lantern Pharma (NASDAQ: LTRN) reported Q2 EPS of ($0.40), $0.13 better than the analyst estimate of ($0.53).
For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GameStop CEO Cohen buys 1.15M shares
- Bernstein SocGen Group Upgrades Engie SA (ENGI:FP) (ENGIY) to Outperform
- Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
